Benitec Biopharma Inc Aktie News

Alle sechs Patienten der Kohorte 1 (niedrige Dosis BB-301) haben den vollständigen 12-monatigen Nachbeobachtungszeitraum nach der Behandlung abgeschlossen, und Kohorte 2 (hohe Dosis BB-301) ist vollständig eingeschrieben, wobei alle drei Patienten sicher behandelt wurden Ein Type-C-Meeting fand mit der U.S. Food and Drug Administration in 3Q2026 statt, um das Design der zulassungsrelevanten Stu...

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating dis...

- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients d...